Grünewald, S., Politz, O., Bender, S., Héroult, M., Lustig, K., Thuss, U., . . . Ziegelbauer, K. (2019). Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. Int J Cancer.
Citação norma ChicagoGrünewald, Sylvia, et al. "Rogaratinib: A Potent and Selective Pan‐FGFR Inhibitor With Broad Antitumor Activity in FGFR‐overexpressing Preclinical Cancer Models." Int J Cancer 2019.
Citação norma MLAGrünewald, Sylvia, et al. "Rogaratinib: A Potent and Selective Pan‐FGFR Inhibitor With Broad Antitumor Activity in FGFR‐overexpressing Preclinical Cancer Models." Int J Cancer 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.